Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

Journal of Cellular Biochemistry

Volumn 91, Issue 4, 2004, Pages 718-729

  Keller, Evan T ^a,d   Brown, Julie ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BMP; Bone metastases; Bone remodeling; ET 1; Metastasis; OPG; Prostate cancer; RANKL

Indexed keywords

ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE DEVELOPMENT; BONE METASTASIS; BONE REMODELING; CANCER CELL; MICROENVIRONMENT; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR GROWTH; ANIMAL; BONE TUMOR; CYTOLOGY; HUMAN; MALE; METABOLISM; METASTASIS; OSTEOBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; BONE NEOPLASMS; HUMANS; MALE; OSTEOBLASTS; OSTEOGENESIS; OSTEOLYSIS; PROSTATIC NEOPLASMS;

EID: 11344267803     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10662     Document Type: Review

References (135)

1. Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O'Brien CA, Economides AN, Stahl N, Jilka RL, Manolagas SC. 2000. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: Antagonism by noggin. J Bone Miner Res 15:663-673.
2. Abrams H, Spiro R, Goldstein N. 1950. Metastases in carcinoma. Cancer 3:74-85.
3. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA. 1994. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54:2372-2377.
4. Alam AS, Gallagher A, Shankar V, Ghatei MA, Datta HK, Huang CL, Moonga BS, Chambers TJ, Bloom SR, Zaidi M. 1992. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: Implications for the vascular control of bone resorption. Endocrinology 130: 3617-3624.
5. Asahina I, Sampath TK, Nishimura I, Hauschka PV. 1993. Human osteogenic protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor cells derived from newborn rat calvaria. J Cell Biol 123:921-933.
6. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM. 2000. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640-649.
7. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM. 2001. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370-377.
8. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC. 1998. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78:1219-1223.
9. Barnes J, Anthony CT, Wall N, Steiner MS. 1995. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 13:337-343.
10. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RG. 1992. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66:1159-1163.
11. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P, Dogliotti L, Angeli A. 1996. Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension. Br J Cancer 73:1581-1587.
12. Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. 1999. Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. Prostate 39: 187-197.
13. Boyce BF, Hughes DE, Wright KR, Xing L, Dai A. 1999a. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 79:83-94.
14. Boyce BF, Yoneda T, Guise TA. 1999b. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6:333-347.
15. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. 2001. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611-616.
16. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22.
17. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 31:578-583.
18. Carlin BI, Andriole GL. 2000. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989-2994.
19. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. 1983. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918-924.
20. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, Ahmed T. 2000. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83:360-365.
21. Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T. 2000. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632-637.
22. Clarke NW, McClure J, George NJ. 1991. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68:74-80.
23. Clarke NW, McClure J, George NJ. 1993. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 24:286-290.
24. Coleman RE. 1997. Skeletal complications of malignancy. Cancer 80:1588-1594.
25. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. 2003. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97:739-747.
26. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. 1999. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14:915-922.
27. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K. 2001. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540.
28. Deftos LJ. 2000. Prostate carcinoma: Production of bioactive factors. Cancer 88:3002-3008.
29. Demers LM, Costa L, Lipton A. 2000. Biochemical markers and skeletal metastases. Cancer 88:2919-2926.
30. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424.
31. Ducy P, Karsenty G. 2000. The family of bone morphogenetic proteins. Kidney Int 57:2207-2214.
32. Ducy P, Schinke T, Karsenty G. 2000. The osteoblast: A sophisticated fibroblast under central surveillance. Science 289:1501-1504.
33. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. 2003. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9:2587-2597.
34. Galasko CS. 1986. Skeletal metastases. Clin Orthop 210: 18-30.
35. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096-4102.
36. Goltzman D, Bolivar I, Rabbani SA. 1992. Studies on the pathogenesis of osteoblastic metastases by prostate cancer. Adv Exp Med Biol 324:165-171.
37. Goltzman D, Karaplis AC, Kremer R, Rabbani SA. 2000. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88:2903-2908.
38. Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL. 1999. Differentiation of human marrow stromal precursor cells: Bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J Bone Miner Res 14:1522-1535.
39. Groeneveld EH, Burger EH. 2000. Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol 142:9-21.
40. Guise TA. 2000. Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898.
41. Guise TA, Mundy GR. 1998. Cancer and bone. Endocr Rev 19:18-54.
42. Hall BK, Miyake T. 2000. All for one and one for all: Condensations and the initiation of skeletal development. Bioessays 22:138-147.
43. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. 1997. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57:4427-4431.
44. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. 1994. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24:204-211.
45. Hogan BL. 1996. Bone morphogenetic proteins in development. Curr Opin Genet Dev 6:432-438.
46. Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623.
47. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain, and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528.
48. Hullinger TG, Taichman RS, Linseman DA, Somerman MJ. 2000. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem 78:607-616.
49. Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y, Osada Y, Sugimura T, Terada M. 1997a. Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs published erratum appears in Oncogene 1997 Aug 28;15(9):1121. Oncogene 14:1377-1382.
50. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. 1997b. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022-5027.
51. Jena N, Martin-Seisdedos C, McCue P, Croce CM. 1997. BMP7 null mutation in mice: Developmental defects in skeleton, kidney, and eye. Exp Cell Res 230:28-37.
52. Karaplis AC, Vautour L. 1997. Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr Opin Nephrol Hypertens 6:308-313.
53. Karsenty G. 2000. Bone formation and factors affecting this process. Matrix Biol 19:85-89.
54. Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T. 1990. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 172:295-299.
55. Katagiri T, Akiyama S, Namiki M, Komaki M, Yamaguchi A, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. 1997. Bone morphogenetic protein-2 inhibits terminal differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and myogenin. Exp Cell Res 230:342-351.
56. Killian CS, Corral DA, Kawinski E, Constantine RI. 1993. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192:940-947.
57. Kim KJ, Itoh T, Kotake S. 1997. Effects of recombinant human bone morphogenetic protein-2 on human bone marrow cells cultured with various biomaterials. J Biomed Mater Res 35:279-285.
58. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA. 2000. Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60:2840-2844.
59. Kimura G, Sugisaki Y, Masugi Y, Nakazawa N. 1992. Calcification in human osteoblasts cultured in medium conditioned by the prostatic cancer cell line PC-3 and prostatic acid phosphatase. Urol Int 48:25-30.
60. Kingsley DM, Bland AE, Grubber JM, Marker PC, Russell LB, Copeland NG, Jenkins NA. 1992. The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily. Cell 71:399-410.
61. Knutsen R, Wergedal JE, Sampath TK, Baylink DJ, Mohan S. 1993. Osteogenic protein-1 stimulates proliferation and differentiation of human bone cells in vitro. Biochem Biophys Res Commun 194:1352-1358.
62. Kong YY, Boyle WJ, Penninger JM. 1999. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation, and lymphocyte development. Immunol Cell Biol 77:188-193.
63. La M, Reid JJ. 1995. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 22:315-323.
64. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
65. Laitinen M, Marttinen A, Aho AJ, Lindholm TS. 1998. Bone morphogenetic protein in bone neoplasms: Comparison of different detection methods. Eur Surg Res 30:168-174.
66. Lange PH, Vessella RL. 1998. Mechanisms, hypotheses, and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 17:331-336.
67. Le Brun G, Aubin P, Soliman H, Ropiquet F, Villette JM, Berthon P, Creminon C, Cussenot O, Fiel J. 1999. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 11:157-162.
68. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR. 2002. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62: 5564-5570.
69. Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, Lieberman JR. 2003. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21: 62-72.
70. Li IW, Cheifetz S, McCulloch CA, Sampath KT, Sodek J. 1996. Effects of osteogenic protein-1 (OP-1, BMP-7) on bone matrix protein expression by fetal rat calvarial cells are differentiation stage specific. J Cell Physiol 169: 115-125.
71. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. 2001. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47:212-221.
72. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW. 2001. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61:4038-4047.
73. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. 1997. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157:539-543.
74. Maliakal JC, Asahina I, Hauschka PV, Sampath TK. 1994. Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. Growth Factors 11:227-234.
75. Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. New Engl J Med 332:305-311.
76. Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS, Yamanaka H. 2003. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54:268-274.
77. Merino R, Rodriguez-Leon J, Macias D, Ganan Y, Economides AN, Hurle JM. 1999. The BMP antagonist gremlin regulates outgrowth, chondrogenesis, and programmed cell death in the developing limb. Development 126:5515-5522.
78. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615.
79. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. 2001. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436.
80. Moul JW, Lipo DR. 1999. Prostate cancer in the late 1990s: Hormone refractory disease options. Urol Nurs 19:125-31; quiz 132-3.
81. Munk PL, Poon PY, O'Connell JX, Janzen D, Coupland D, Kwong JS, Gelmon K, Worsley D. 1997. Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiol 26:434-437.
82. Nelson JB, Carducci MA. 2000. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 85(Suppl 2):45-48.
83. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. 1995. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949.
84. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. 1996. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663-668.
85. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N. 1999. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53:1063-1069.
86. Nielsen OS, Munro AJ, Tannock IF. 1991. Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509-524.
87. Nifuji A, Noda M. 1999. Coordinated expression of noggin and bone morphogenetic proteins (BMPs) during early skeletogenesis and induction of noggin expression by BMP-7. J Bone Miner Res 14:2057-2066.
88. Nifuji A, Kellermann O, Noda M. 1999. Noggin expression in a mesodermal pluripotent cell line C1 and its regulation by BMP. J Cell Biochem 73:437-444.
89. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. 2001. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61:2572-2578.
90. Papapoulos SE, Hamdy NA, van der Pluijm G. 2000. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 88:3047-3053.
91. Parfitt AM. 2000. The mechanism of coupling: A role for the vasculature. Bone 26:319-323.
92. Patel KV, Schrey MP. 1995. Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: A proposed mitogen for human breast fibroblasts. Br J Cancer 71:442-447.
93. Patel KV, Sheth HG, Schrey MP. 1997. Stimulation or endothelin-1 secretion by human breast cancer cells through protein kinase A activation: A possible novel paracrine loop involving breast fibroblast-derived prostaglandin E2. Mol Cell Endocrinol 126:143-151.
94. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. 2001. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586.
95. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. 1987. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13:41-49.
96. Perkel VS, Mohan S, Baylink DJ, Linkhart TA. 1990. An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP. J Clin Endocrinol Metab 71:533-535.
97. Pirtskhalaishvili G, Nelson JB. 2000. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44:77-87.
98. Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. 1997. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 172:137-145.
99. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Elton RA. 1993. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 72:933-936.
100. Raval P, Hsu HH, Schneider DJ, Sarras MP, Jr., Masuhara K, Bonewald LF, Anderson HC. 1996. Expression of bone morphogenetic proteins by osteoinductive and non-osteoinductive human osteosarcoma cells. J Dent Res 75:1518-1523.
101. Reddi AH. 1997. Bone morphogenetic proteins: An unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev 8:11-20.
102. Roland S. 1958. Calcium studies in ten cases of osteoblastic prostatic metastasis. J Urol 79:339-342.
103. Roodman GD. 1996. Advances in bone biology: The osteoclast. Endocr Rev 17:308-332.
104. Rosol TJ. 2000. Pathogenesis of bone metastases: Role of tumor-related proteins. J Bone Miner Res 15:844-850.
105. Roudier M, Sherrard D, True L, Ott-Ralp S, Meligro C, MBerrie M, Soo C, Felise D, Quinn JE, Vessella R. 2000. Heterogenous bone histomorphometric patterns in metastatic prostate cancer. J Bone Miner Res 15S1:S567.
106. Sasaki T, Hong MH. 1993a. Endothelin-1 localization in bone cells and vascular endothelial cells in rat bone marrow. Anat Rec 237:332-337.
107. Sasaki T, Hong MH. 1993b. Localization of endothelin-1 in the osteoclast. J Electron Microsc (Tokyo) 42:193-196.
108. Schrey MP, Patel KV. 1995. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72:1412-1419.
109. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
110. Solloway MJ, Dudley AT, BikofT EK, Lyons KM, Hogan BL, Robertson EJ. 1998. Mice lacking Bmp6 function. Dev Genet 22:321-339.
111. Stern PH, Tatrai A, Semler DE, Lee SK, Lakatos P, Strieleman PJ, Tarjan G, Sanders JL. 1995. Endothelin receptors, second messengers, and actions in bone. J Nutr 125:2028S-2032S.
112. Suzuki A, Kaneko E, Maeda J, Ueno N. 1997. Mesoderm induction by BMP-4 and -7 heterodimers. Biochem Biophys Res Commun 232:153-156.
113. Szostak MJ, Kyprianou N. 2000. Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep 7:699-706.
114. Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC. 1998. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110: 559-574.
115. Takuwa Y, Masaki T, Yamashita K. 1990. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170:998-1005.
116. Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim EE, Hopwood VL, Pathak S, Eschenbach ACv, Chung LWK. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581.
117. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. 1999. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451-448.
118. Tsuji K, Ito Y, Noda M. 1998. Expression of the PEBP2al-phaA/AML3/CBFA1 gene is regulated by BMP4/7 heterodimer and its overexpression suppresses type I collagen and osteocalcin gene expression in osteoblastic and nonosteoblastic mesenchymal cells. Bone 22:87-92.
119. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. 1985. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 57: 721-723.
120. Vinholes J, Coleman R, Eastell R. 1996. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging, and assessment of response to cancer treatment. Cancer Treat Rev 22:289-331.
121. Wan M, Shi X, Feng X, Cao X. 2001. Transcriptional mechanisms of BMP-induced osteoprotegrin gene expression. J Biol Chem 276:10119-10125.
122. Weber KL, Bolander ME, Rock MG, Pritchard D, Sarkar G. 1998. Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms. J Orthop Res 16:8-14.
123. Wlosarski K, Reddi AH. 1987. Tumor cells stimulate in vivo periosteal bone formation. Bone Miner 2:185-192.
124. Wozney JM. 1992. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 32:160-167.
125. Wrana JL. 2000. Regulation of Smad activity. Cell 100:189-192.
126. Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Katagiri T, Wozney JM, Rosen V, Yoshiki S. 1996. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2, and MC3T3-G2/PA6. Biochem Biophys Res Commun 220:366-371.
127. Yamashita T, Yoshitake H, Tsuji K, Kawaguchi N, Nabeshima Y, Noda M. 2000. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. Endocrinology 141:438-445.
128. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415.
129. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. 1998a. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
130. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998b. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
131. Yin J, Grubbs B, Cui Y, Weu-Wong J, Wessale J, Padley R, Guise T. 2000. Endothelin A receptor blockade inhibits osteoblastic metastases. J Bone Miner Res 15:8201.
132. Yoneda T. 1998. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 34:240-245.
133. Yorimitsu K, Moroi K, Inagaki N, Saito T, Masuda Y, Masaki T, Seino S, Kimura S. 1995. Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophys Res Commun 208:721-727.
134. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. 2001. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
135. Zimmerman LB, De Jesus-Escobar JM, Harland RM. 1996. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86:599-606.